Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 2Solid Tumours 1Multiple Endocrine Neoplasia Type 1 1Lymphoma 1Long QT Syndrome 1Hot Flashes 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

Rituximab 57Cyclophosphamide 56fludarabine 37fludarabine phosphate 31Filgrastim 27Etoposide 22Bortezomib 20Melphalan 19Gemcitabine 19Cytarabine 17Bendamustine Hydrochloride 17Peripheral Blood Stem Cell Transplantation 16Vincristine 15pembrolizumab 14aldesleukin 13Prednisone 13Doxorubicin 12Dexamethasone 12Busulfan 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Sirolimus 11sargramostim 10obinutuzumab 10Lenalidomide 10romidepsin 9Radiotherapy 9Rifampin 8Paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma × Moxifloxacin × Clear all
NCT01525394 2023-06-22

A Double-Blind Study in Healthy Volunteers to Assess the Effect of E7080 on the QTc Interval

Eisai Inc.

Phase 1 Completed
52 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡